Home
|
English
|
简体中文
|
Sign In
or
Sign Up
ESG Investing
What is ESG?
History of ESG Investment
ESG Investment Approach
ESG Investment Practice
Standards and Initiatives
ESG Data
ESG Rating Methodology
STαR ESG Data Platform
ESG Risk Radar System
ESG Investment Strategy
Chinese Company's ESG Rating Search
Sustainable Finance
ESG Due Diligence
ESRM
Capacity Building
Policy Advisory
China Green Finance Policy Database
Green Bond
Climate Change
Carbon Footprint
Physical Risks
PANDA Climate Data
Climate Scenario Analysis
Climate Stress Testing
Publications
Responsible Investment Annual Report
ESG Performance Research
Climate Change
Green Bonds
ESG Issues
Industry Research
Other Research
News
About Us
Introduction
Contact Us
SynTao GF Team
Join Us
Internships
China SIF
News
Press Releases
行业活动
专题研究
ESG评级洞察
ESG风险扫描
Press Releases
Home
>
News
>
Press Releases
Pharmaceutical company that provides Remdesivir has excellent ESG performance
Views : 986
Update time : 2020-02-10 14:43:00
Chinese version only.
Previous :
Epidemic Control of Listed Companies From the Perspective of ESG
Next :
ESG Assessment of the Response of Shanghai Stock Index 50 Listed Companies to the Epidemic
